Display options
Cite
Lin SF, Lin JD, Hsueh C, et al. Effects of roniciclib in preclinical models of anaplastic thyroid cancer. Oncotarget. 2017;8(40):67990-68000doi: 10.18632/oncotarget.19092.
Lin, S. F., Lin, J. D., Hsueh, C., Chou, T. C., & Wong, R. J. (2017). Effects of roniciclib in preclinical models of anaplastic thyroid cancer. Oncotarget, 8(40), 67990-68000. https://doi.org/10.18632/oncotarget.19092
Lin, Shu-Fu, et al. "Effects of roniciclib in preclinical models of anaplastic thyroid cancer." Oncotarget vol. 8,40 (2017): 67990-68000. doi: https://doi.org/10.18632/oncotarget.19092
Lin SF, Lin JD, Hsueh C, Chou TC, Wong RJ. Effects of roniciclib in preclinical models of anaplastic thyroid cancer. Oncotarget. 2017 Jul 08;8(40):67990-68000. doi: 10.18632/oncotarget.19092. eCollection 2017 Sep 15. PMID: 28978090; PMCID: PMC5620230.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jul 08;8(40):67990-68000. doi: 10.18632/oncotarget.19092. eCollection 2017 Sep 15.

Effects of roniciclib in preclinical models of anaplastic thyroid cancer.

Oncotarget

Shu-Fu Lin, Jen-Der Lin, Chuen Hsueh, Ting-Chao Chou, Richard J Wong

Affiliations

  1. Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.
  2. Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.
  3. Laboratory of Preclinical Pharmacology Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  4. Current address: PD Science, Inc., Paramus, NJ, USA.
  5. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

PMID: 28978090 PMCID: PMC5620230 DOI: 10.18632/oncotarget.19092

Abstract

Many human cancers have altered cyclin-dependent kinase activity. Inhibition of cyclin-dependent kinases may arrest cell cycle progression and represents an important strategy in the treatment of malignancies. We evaluated the therapeutic effects of roniciclib, a cyclin-dependent kinase inhibitor, as a treatment for anaplastic thyroid cancer. Roniciclib inhibited anaplastic thyroid cancer cell proliferation in a dose-dependent manner. Roniciclib activated caspase-3 activity and induced apoptosis. Cell cycle progression was arrested in G2/M phase.

Keywords: anaplastic thyroid cancer; cyclin-dependent kinase; roniciclib

Conflict of interest statement

CONFLICTS OF INTEREST There is no conflicts of interest.

References

  1. Thyroid. 2000 Jul;10(7):587-94 - PubMed
  2. Genes Cells. 2002 Nov;7(11):1173-82 - PubMed
  3. Cancer. 2005 Apr 1;103(7):1330-5 - PubMed
  4. Oncogene. 2005 Apr 18;24(17):2909-15 - PubMed
  5. Science. 2005 Dec 2;310(5753):1499-504 - PubMed
  6. Pharmacol Rev. 2006 Sep;58(3):621-81 - PubMed
  7. J Biol Chem. 2007 Feb 2;282(5):2776-84 - PubMed
  8. J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41 - PubMed
  9. Am J Clin Oncol. 2008 Oct;31(5):460-4 - PubMed
  10. Mol Cell Biol. 2009 Feb;29(4):1059-71 - PubMed
  11. Nat Rev Cancer. 2009 Mar;9(3):153-66 - PubMed
  12. Thyroid. 2011 Jan;21(1):25-30 - PubMed
  13. Int J Oncol. 1994 Mar;4(3):583-6 - PubMed
  14. Cell Death Differ. 2012 Jan;19(1):107-20 - PubMed
  15. Thyroid. 2011 Nov;21(11):1183-9 - PubMed
  16. BMC Cancer. 2011 Nov 01;11:469 - PubMed
  17. Trends Cell Biol. 2012 Mar;22(3):169-75 - PubMed
  18. Mol Cancer Ther. 2012 Oct;11(10):2265-73 - PubMed
  19. PLoS One. 2012;7(10):e46726 - PubMed
  20. Thyroid. 2012 Nov;22(11):1104-39 - PubMed
  21. Nat Rev Mol Cell Biol. 2012 Dec;13(12):789-803 - PubMed
  22. Genes Dev. 2014 Aug 15;28(16):1800-14 - PubMed
  23. Oncologist. 2014 Nov;19(11):1148-55 - PubMed
  24. Nat Rev Drug Discov. 2015 Feb;14(2):130-46 - PubMed
  25. Gland Surg. 2015 Feb;4(1):44-51 - PubMed
  26. Cell. 2015 Sep 24;163(1):174-86 - PubMed
  27. Nat Rev Mol Cell Biol. 2016 May;17(5):280-92 - PubMed
  28. Expert Rev Endocrinol Metab. 2016 May;11(3):235-237 - PubMed
  29. J Clin Endocrinol Metab. 1997 Jun;82(6):1857-62 - PubMed

Publication Types